Newsletter | July 2, 2026

07.02.26 -- What Happens When Sponsors Pull Back Mid-Trial?

SPONSOR

This webinar highlights challenges sponsors face managing CRO change orders, including scattered communication, limited budget visibility, and difficulty tracking revisions and impact. It emphasizes the need for structured processes and technology to improve collaboration, financial transparency, and auditability. Attendees will learn best practices for managing budgets, tracking projections vs. actuals, and reducing inefficiencies in study financial management.

REGULATORY COMPLIANCE

FDA's HALO Platform And Elsa 4.0: Five Critical Risks For Sponsors

Discover five critical risks created by HALO's architecture and Elsa 4.0's expanded capabilities. Then, learn how to implement practical safeguards sponsors to implement immediately.

A Strategic Imperative For Operations Teams In Oncology Clinical Trials

The oncology landscape is growing but faces high screen-fail rates and trial complexity. To succeed, teams must move past traditional playbooks and adopt centralized pre-screening pipelines.

GLP Compliance In A Modern Lab: What Is Actually Required?

GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

AI, Virtual Participants, and the Evolving FDA Regulatory Landscape

Understanding emerging requirements around transparency, risk, and governance is essential for responsibly advancing AI-driven innovation in regulated environments.

Clinical Research Update: The New FDA Form 1572 is Available

The FDA released an updated Form 1572, approved through September 30, 2026. Stay current with the new form to ensure seamless compliance for your next clinical trial update.

5 Trends To Watch This Year

Explore 2026 policy trends across drug‑pricing actions, affordability pressures, value‑driven evaluation, shifts in global innovation, and new AI regulatory applications.

OUTSOURCING

What Really Happens At The Site When Sponsors Pull Back Mid-Trial

When sponsors slow or reduce operational spending due to financial pressure, strategic pivots, or internal restructuring, sites — and patients — suffer. Curo Research CCO Amy Bland explains how sponsors can better manage operational changes.

De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept

Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.

Medical Writing Services To Support Every Submission Milestone

Ensure accurate, compliant, and impactful documentation with Altasciences' experienced medical writers and regulatory experts.

The Fastest-Growing Trial Operations Platform

A unified platform connects teams, digitizes workflows, and delivers real-time insights to speed study startup, strengthen oversight, and keep trials inspection-ready end to end.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Thursday edition of the Clinical Leader newsletter, focusing on Outsourcing Models and Regulatory & Compliance. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: